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with the physician/Less than 6 months of survival/Intravenous
administration). The factors that inﬂuence more on the treatment
preferences were, symptoms’ control (31% of the patients), con-
ﬁdence with the physician (21.6%) and immediate toxicity
(18.7%). CONCLUSION: Through a conjoint analysis we may
conclude that the most important attributes for the patients were
symptoms’ control followed by conﬁdence with their physician.
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OBJECTIVES: Sunitinib malate is an oral, tyrosine kinase inhibi-
tor that targets VEGFRs, PDGFRs, KIT, RET and FLT3, with
antitumour and antiangiogenic effects. Sunitinib demonstrated
statistically superior efﬁcacy and HRQOL over IFN-alfa as ﬁrst-
line mRCC therapy (P < 0.001) in an international, randomised
phase III trial [Motzer et al. NEJM 2007;356:115–24]. These
analyses examine the association between geography and treat-
ment effect on patient-reported outcomes (PROs). METHODS:
Patients with mRCC (N = 750) were randomised 1 : 1 to suni-
tinib 50 mg/day orally in 6-week cycles (4 weeks on, 2 weeks off)
or IFN-alfa (9 MU SC TIW). HRQOL was assessed on days 1
and 28 of each cycle using the following instruments: 1) FACT-
Kidney Symptom Index (FKSI) and its disease-related symptom
subscale (FKSI-DRS); 2) Functional Assessment of Cancer
Therapy-General (FACT-G) and its 4 subscales; and 3)
population-preference-based health state utility score (EQ-5D
Index) and patient self-rated overall health state (EQ-VAS) from
the EQ-5D self-report questionnaire. Data were analysed using
repeated-measures mixed-effects models for the EU+ (France,
Germany, Italy, Poland, Russia, Spain, UK, plus Australia and
Canada; n = 400) and US (n = 346) subsamples. RESULTS: Suni-
tinib provided a signiﬁcant beneﬁt compared with IFN-alfa in
the overall post-baseline least-square means for in all 9 PRO
endpoints (P < 0.05), except EQ-5D in the US subsample
(P = 0.4105). Most of the 9 FKSI-DRS items also favoured suni-
tinib. These ﬁndings were consistent with the overall sample
results. Larger between-treatment differences were generally
observed in the EU+ subsample compared with the US sub-
sample. CONCLUSION: In both Europe and the US, sunitinib
offers consistent HRQOL and kidney cancer-related symptoms
advantages compared with IFN-alfa in the ﬁrst-line treatment of
mRCC. These advantages were more pronounced in the EU+
sample and may reﬂect differences in treatment experience or
underlying differences in HRQOL reporting.
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OBJECTIVES: Hot ﬂashes are important adverse effects of
androgen deprivation therapies (ADT) in prostate cancer
patients. The prevalence of hot ﬂashes in patients undergoing
ADT is approximately 70–80%. Fifty-ﬁve percent of patients
report distress due to their hot ﬂashes. The Hot Flash Diary
(HFD) developed by the North Central Cancer Treatment
Group/Mayo Clinic measures patient’s daily assessment of hot
ﬂash frequency and severity and enables calculation of a hot
ﬂash score. Severity is measured on a scale from 1 (“Mild”) to
4 (“Very severe”). To measure hot ﬂashes in prostate cancer
patients cross-culturally, we performed the translation/
adaptation and linguistic validation of the HFD for use in 9
countries: Canada (French/English), Czech Republic, France,
Germany, Hungary, The Netherlands, Spain (Catalan/Spanish),
US (Spanish), and UK. METHODS: The translation/adaptation
and linguistic validation of the HFD followed an established and
rigorous method to ensure conceptual equivalence between the
original and translated versions. The methodology consisted of
10 steps: 1) item deﬁnition development; 2) two forward trans-
lations; 3) reconciliation; 4) back-translation; 5) source and
back-translated text comparison; 6) bilingual expert review; 7)
ﬁnalization; 8) harmonization; 9) comprehension testing with
patients; and 10) post-testing review/revision. RESULTS: Lin-
guistic and conceptual issues were identiﬁed during translation. It
proved difﬁcult to ﬁnd precise equivalents for adjectives describ-
ing the degree of hot ﬂash (e.g. ‘mild’, ‘moderate’, ‘severe’) in
several languages. Additional problems were mainly related to
semantics and syntax. Overall, the HFD was well understood by
the patients and they encountered little difﬁculty in its comple-
tion. CONCLUSION: Linguistic validity of the HFD for 9 coun-
tries was conﬁrmed. International prostate cancer trials are
currently underway and cross-cultural data on hot ﬂashes will be
available to provide international comparison of this very both-
ersome adverse effect of ADT.
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OBJECTIVES: The Consequence of Screening in Breast Cancer
questionnaire (COS-BC) assesses the psychosocial consequences
of abnormal and false-positive screening mammography. It has
two parts; one covering the period between abnormal screening
and ﬁnal diagnosis and one relating to the period following being
declared free from cancer. The ﬁrst aim of the study was to assess
if COS (i.e. COS-BC without the breast speciﬁc items) was rel-
evant for persons having false-positive lung cancer screening
results. The second was to develop new items speciﬁcally relevant
to participants in lung cancer screening. METHODS: A ran-
domised study of lung cancer screening was launched in
Denmark in 2005. Five focus groups were held with 20 people
(13 women and 7 men; mean age 60.0 years) who had received
an abnormal screening result in the prevalence round and were
recalled for a scan after 3 months. They discussed their thoughts
and feelings after being recalled and after receiving the ﬁnal
false-positive diagnosis. They completed the COS and discussed
its relevance to their own experiences. The face and content
validity of new items developed after the focus groups was tested
by means of interviews with 6 participants from the focus groups
RESULTS: The items in the COS were all relevant for lung cancer
screening. Three themes were extracted from the audio-taped
interviews. Stigmatisation, Self-blame and Focus on symptoms.
Twenty-six new items for part I and 16 for part II of the ques-
tionnaire (COS-LC) were generated. CONCLUSION: There are
many common psychosocial consequences of abnormal and
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